Volume 30, Number 9—September 2024
EIN Research Letter
Recognition of Antifungal-Resistant Dermatophytosis by Infectious Diseases Specialists, United States
Abstract
Antifungal-resistant dermatophyte infections have recently emerged as a global public health concern. A survey of US infectious diseases specialists found that only 65% had heard of this issue and just 39% knew how to obtain testing to determine resistance. Increased clinician awareness and access to testing for antifungal-resistant dermatophytosis are needed.
Dermatophytosis (i.e., ringworm, tinea) is a common superficial fungal skin infection caused by dermatophyte molds (1). In the past decade, widespread outbreaks of antifungal-resistant dermatophytosis have occurred in South Asia because of the spread of Trichophyton indotineae fungus, which causes extensive pruritic plaques on the trunk, extremities, groin, and face in immunocompetent persons (2–4). Unlike typical dermatophyte skin infections, those involving T. indotineae fungus often do not resolve with over-the-counter topical antifungals or oral terbinafine (first-line systemic therapy) (2,3).
T. indotineae fungus has been detected in at least 11 US states, and recalcitrant dermatophytosis caused by antifungal-resistant T. rubrum fungus also has been reported (2,5,6). Affected patients have experienced diagnostic delays and received inappropriate therapies, including topical corticosteroids, which can worsen dermatophytosis (2). Antifungal-resistant dermatophytosis cases in the United States probably are underrecognized because this condition is not reportable to public health authorities in any state (https://www.cdc.gov/fungal/php/case-reporting) and most superficial fungal infections are not confirmed with diagnostic testing (7). Further, laboratory capacity to identify dermatophyte species and perform antifungal-susceptibility testing (AFST) may be limited, given that definitive identification of certain species, such as T. indotineae, requires advanced molecular techniques (e.g., using internal transcribed spacer region sequencing) and most clinical laboratories do not perform AFST for molds (2,8).
Antifungal-resistant dermatophytosis cases might require infectious diseases (ID) clinician consultation both to manage antifungal use and because of the potential effect of these infections on highly immunocompromised patients. Understanding ID clinicians’ level of awareness regarding antifungal-resistant dermatophytosis and access to laboratory testing could improve strategies to increase disease recognition and facilitate early appropriate treatment. Therefore, we surveyed ID clinicians by using the Emerging Infections Network (EIN) (https://ein.idsociety.org), a sentinel network of ID physicians and other ID specialists.
During December 2023, EIN distributed a survey link to ≈3,000 member subscribers on 3 separate occasions ≈1 week apart. EIN queries are designated as non–human subjects research by the institutional review board of the University of Iowa.
In total, we received 158 responses (Table). The most common practice setting was university hospital (47%), followed by community hospital (16%) and nonuniversity teaching hospital (12%). Most respondents were adult ID physicians (80%), followed by pediatric ID physicians (12%), pharmacists (4%), nurse practitioners, physician assistants or physician associates (1%), or other (3%). Overall, 103 (65%) respondents had heard of antifungal-resistant dermatophytosis before receiving the survey; among those, most (58%) had heard of it through previous EIN listserv emails. Seventeen percent of respondents reported seeing or consulting on a patient who had dermatophytosis that was potentially resistant to treatment or concerning for resistance within the previous year.
Approximately half (47%) of respondents reported that if they saw a patient with potentially resistant dermatophytosis, they either would not be able to obtain laboratory testing to determine the species (16%) or were unsure whether they could obtain such testing (31%) (Table). Likewise, most respondents (61%) reported they would either not be able to obtain testing to determine if a dermatophyte was resistant to antifungals (16%) or were unsure whether they could obtain such testing (45%).
In summary, our survey found that approximately one third (35%) of ID clinicians had not heard of antifungal-resistant dermatophytosis. Only 53% of respondents reported knowing how to obtain access to dermatophyte speciation testing, and even fewer (39%) reported knowing how to obtain testing for dermatophyte resistance (Table). Those findings probably reflect the relatively recent recognition of these infections in the United States and the fact that testing to identify T. indotineae and other resistant dermatophyte species is limited to select US mycology reference centers and public health laboratories (2,8).
Dermatophyte species identification and AFST are critical to guiding antifungal treatment decisions for patients with potentially resistant dermatophytosis and for monitoring population-level trends in resistance profiles to inform treatment guidelines (8). National guidelines for treating antifungal-resistant dermatophytosis are lacking, but the azole antifungal itraconazole has been used successfully for patients with dermatophytosis caused by T. indotineae and terbinafine-resistant T. rubrum fungi (2,9). However, clinicians should be aware of challenges with itraconazole, including pharmacokinetic variability (e.g., absorption), insurance coverage, drug–drug interactions, need for prolonged treatment (e.g., >6 weeks), and reports of emerging itraconazole-resistant T. indotineae and T. rubrum fungi (2,6,9,10).
One limitation of our survey is its low response rate and nonrepresentative nature. Furthermore, the survey might overestimate clinician awareness of antifungal-resistant dermatophytosis and laboratory testing access if clinicians experienced in this topic were likelier to respond. Despite those limitations, our survey highlights a need for increased awareness of antifungal-resistant dermatophytosis and increased laboratory capacity to identify and perform susceptibility testing for dermatophytes to address this emerging public health concern.
Healthcare professionals can find information about recognizing, diagnosing, treating, and reporting emerging dermatophyte infections online (https://www.aad.org/member/clinical-quality/clinical-care/emerging-diseases/dermatophytes), including information about laboratories that can perform testing (https://www.aad.org/member/clinical-quality/clinical-care/emerging-diseases/dermatophytes/recognizing-trichophyton-indotineae#testing). Those websites were developed as a collaboration between the Centers for Disease Control and Prevention and the American Academy of Dermatology’s Emerging Diseases Task Force.
Dr. Gold is a medical epidemiologist in the Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. His research interests include the epidemiology and prevention of fungal infections.
Acknowledgment
This work was supported by Cooperative Agreement Number 5 (grant no. NU50CK000574), funded by the Centers for Disease Control and Prevention.
References
- Gupta AK, Ryder JE, Chow M, Cooper EA. Dermatophytosis: the management of fungal infections. Skinmed. 2005;4:305–10. DOIPubMedGoogle Scholar
- Caplan AS, Chaturvedi S, Zhu Y, Todd GC, Yin L, Lopez A, et al. Notes from the field: first reported U.S. cases of tinea caused by Trichophyton indotineae—New York City, December 2021–March 2023. MMWR Morb Mortal Wkly Rep. 2023;72:536–7. DOIPubMedGoogle Scholar
- Verma SB, Panda S, Nenoff P, Singal A, Rudramurthy SM, Uhrlass S, et al. The unprecedented epidemic-like scenario of dermatophytosis in India: I. Epidemiology, risk factors and clinical features. Indian J Dermatol Venereol Leprol. 2021;87:154–75. DOIPubMedGoogle Scholar
- Gupta AK, Renaud HJ, Quinlan EM, Shear NH, Piguet V. The growing problem of antifungal resistance in onychomycosis and other superficial mycoses. Am J Clin Dermatol. 2021;22:149–57. DOIPubMedGoogle Scholar
- Cañete-Gibas CF, Mele J, Patterson HP, Sanders CJ, Ferrer D, Garcia V, et al. Terbinafine-resistant dermatophytes and the presence of Trichophyton indotineae in North America. J Clin Microbiol. 2023;61:
e0056223 . DOIPubMedGoogle Scholar - Gu D, Hatch M, Ghannoum M, Elewski BE. Treatment-resistant dermatophytosis: A representative case highlighting an emerging public health threat. JAAD Case Rep. 2020;6:1153–5. DOIPubMedGoogle Scholar
- Benedict K, Wu K, Gold JAW. Healthcare provider testing practices for tinea and familiarity with antifungal-drug-resistant tinea—United States, 2022. J Fungi (Basel). 2022;8:831. DOIPubMedGoogle Scholar
- Lockhart SR, Smith DJ, Gold JAW. Trichophyton indotineae and other terbinafine-resistant dermatophytes in North America. J Clin Microbiol. 2023;61:
e0090323 . DOIPubMedGoogle Scholar - Khurana A, Agarwal A, Agrawal D, Panesar S, Ghadlinge M, Sardana K, et al. Effect of different itraconazole dosing regimens on cure rates, treatment duration, safety, and relapse rates in adult patients with tinea corporis/cruris: a randomized clinical trial. JAMA Dermatol. 2022;158:1269–78. DOIPubMedGoogle Scholar
- Burmester A, Hipler U-C, Uhrlaß S, Nenoff P, Singal A, Verma SB, et al. Indian Trichophyton mentagrophytes squalene epoxidase erg1 double mutants show high proportion of combined fluconazole and terbinafine resistance. Mycoses. 2020;63:1175–80. DOIPubMedGoogle Scholar
Table
Cite This ArticleOriginal Publication Date: August 13, 2024
Table of Contents – Volume 30, Number 9—September 2024
EID Search Options |
---|
|
|
|
Please use the form below to submit correspondence to the authors or contact them at the following address:
Jeremy Gold, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H24-11, Atlanta, GA 30329-4027, USA
Top